Health Catalyst (HCAT)
(Real Time Quote from BATS)
$6.27 USD
-0.07 (-1.10%)
Updated Apr 30, 2024 10:54 AM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HCAT 6.27 -0.07(-1.10%)
Will HCAT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HCAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HCAT
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
HCAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Healthcare (ACHC) Opens Facility to Address Mental Health
Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels
Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)
Other News for HCAT
Health Catalyst to Announce First Quarter 2024 Operating Results and Host Conference Call on Thursday, May 9, 2024
HROW, HCAT and EGRX are among after hour movers
R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space
SMART Global Reports Q2 Results, Joins Health Catalyst And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Health Catalyst just downgraded at KeyBanc, here's why